Diosynth Biotechnology (Research Triangle Park) Announces Agreement with Talecris Biotherapeutics for Process Development and Clinical Production of Recombinant Plasminogen

Published: Apr 02, 2007

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Diosynth Biotechnology announced today that it has signed an agreement with Talecris Biotherapeutics for process development activities and cGMP production of clinical trial material for a unique form of recombinant Plasminogen. Recombinant Plasminogen is an intermediate material used in the manufacture of recombinant Plasmin, a second-generation therapy Talecris is developing for both ophthalmic and thrombolytic indications.

Back to news